SCHEDULE: Perceptive Advisors Discloses 6.4% Stake in Verona Pharma
Beneficial Ownership Report (Schedule 13G Amendment)
Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., reported a 6.4% beneficial ownership stake in Verona Pharma plc as of June 30, 2025.
Summary
- Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. (collectively, the "Reporting Persons") have filed an Amendment No. 2 to their Schedule 13G.
- The Reporting Persons collectively beneficially own 5,507,591 American Depositary Shares (ADSs) of Verona Pharma plc.
- This ownership represents 6.4% of Verona Pharma plc's outstanding ADSs.
- The percentage is calculated based on 86,192,121 ADSs outstanding as of July 31, 2025, as reported in Verona Pharma's Form 10-Q filed with the SEC on August 6, 2025.
- Each ADS represents eight Ordinary Shares of Verona Pharma plc.
- Perceptive Life Sciences Master Fund, Ltd. directly holds the 5,507,591 ADSs, which represent 44,060,728 Ordinary Shares.
- Perceptive Advisors LLC serves as the investment manager to the Master Fund, and Joseph Edelman is the managing member of Perceptive Advisors.
- The filing certifies that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The filing is a routine disclosure of beneficial ownership, providing factual information without indicating positive or negative operational or financial performance.
Stakeholder Impact
- The disclosure of a significant institutional ownership stake provides transparency to shareholders and the market regarding the composition of the company's investor base.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event requiring the filing of this statement. |
| 07/31/2025 | Date as of which the number of outstanding ADSs (86,192,121) was reported by the Issuer. |
| 08/06/2025 | Date Verona Pharma plc filed its Quarterly Report on Form 10-Q, reporting outstanding shares. |
| 08/14/2025 | Date the Schedule 13G Amendment No. 2 was signed and filed. |
Keywords
Verona Pharma, Perceptive Advisors, Joseph Edelman, Perceptive Life Sciences Master Fund, Schedule 13G, Beneficial Ownership, Pharmaceutical, Biotechnology, Healthcare, Investment, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.